Concord Biotech profit drops 30% on 11% revenue fall
FY26 net profit fell to ₹259.23 crore as total income contracted, ending a growth streak. The board has proposed a ₹7.55 per share dividend.
— 3 earlier stories on Concord Biotech Ltd. →What's new
- FY26 net profit fell 30% to ₹259.23 crore as total income contracted 11% to ₹1,107.25 crore.
- Board recommended a final dividend of ₹7.55 per share, with a record date of July 24, 2026.
- Mrs. Ekta Gupta appointed as independent director; ₹3.27 crore exceptional charge recorded for new labor codes.
Why this matters
The 30% profit decline on an 11% revenue fall signals margin compression, not just a top-line issue. For a specialty player like Concord, this suggests either pricing pressure or a shift in product mix away from higher-margin items. The modest dividend offer does little to offset the earnings deterioration.
What we're watching
- Whether management provides a recovery roadmap on the earnings call.
- The breakdown of revenue by segment to identify the source of the contraction.
- If the exceptional charge is a one-off or a preview of ongoing compliance costs.
The full read
Concord Biotech's audited FY26 numbers are in. The company reported a 30% drop in consolidated net profit to ₹259.23 crore. Total income contracted 11% to ₹1,107.25 crore. The profit decline outpaced the revenue drop. Clear margin erosion. The board has proposed a final dividend of ₹7.55 per share, with the record date fixed for July 24, 2026. On the governance front, the company appointed Mrs. Ekta Gupta as an independent director and booked a ₹3.27 crore exceptional charge for the implementation of new national labor codes. The top-line contraction will dominate the conversation. The dividend offer is a routine gesture. It won't distract from the core issue: Concord's profitability profile has weakened materially, and the question is where the margin pressure came from.
Questions answered
- Why did Concord Biotech's profit fall so sharply?
- Net profit declined 30% to ₹259.23 crore as total income contracted 11% to ₹1,107.25 crore. The steeper profit fall indicates a significant margin squeeze during FY26.
- What is the dividend payout?
- The board recommended a final dividend of ₹7.55 per equity share, subject to approval at the upcoming AGM. The record date is set for July 24, 2026.
- What was the exceptional charge for?
- The company recorded an exceptional charge of ₹3.27 crore related to the implementation of new national labor codes.
- How does this compare to the previous year?
- FY25 net profit was ₹371.64 crore on a higher income base. FY26 represents a clear step-down in profitability.
Story so far
All notes on CONCORDBIO →- 29 May 2026 · 8:17 PM IST Concord Biotech profit drops 30% on 11% revenue fall
- 1d ago Concord Biotech wins USFDA nod for generic transplant drug
- 5d ago Concord Biotech's profit falls 30% on a 12% revenue slide
- 5d ago Concord Biotech profit falls 30% as revenue shrinks in FY26